Biosimilars Market Research Reports & Industry Analysis

Biosimilars (otherwise termed follow-on-biologics, or FOBs for short) stand for the versions of biopharmaceuticals, which have the resembling but not identical parent molecule, and are created either by living organisms or from living micro-organisms by way of rDNA (recombinant DNA) or supervised gene expression technologies. The approval of Biosimilars occurs via strictly defined regulatory paths based on whether FOBs have shown comparability with their reference substance.

The worldwide Biosimilars Market is anticipated to surpass a EUR 14.9bn mark by end 2018. The major drivers encompass cost efficiency of biosimilars versus their high-priced analogues, the enlarging thirst for biotechnology drugs, imminent biotech drugs’ patent expiries, the planet’s aging population, and the rising frequency of critical illnesses. The illustrious actors on the global Biosimilars stage encompass Biocon, Intas Biopharmaceuticals, Cipla, Biopartners, Hospira, Wockhardt, Teva Pharmaceutical Industries, Sandoz International, amidst others.

The Catalogue’s research reports offer world, region and nation-wise analyses of the Biosimilars Market development over various time periods. The researches are lavish with discussions of the Biosimilars Industry growth rate, structure and capacity. The market trends, growth obstacles/stimulators, key products and those in R&D stage, and more issues are studied in the reports. Additionally, the research reports indicate and profile the leading players and hoped-for entrants, and offer market projections and forecasts.

Found 111 publications
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update US$ 560.00

Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update Humira, Enbrel and Remicade ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 124 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update US$ 335.00

Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-Her2 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 84 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update US$ 280.00

Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 56 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update US$ 335.00

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-CD20 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 74 pages
Biosimilars in Oncology: Update Bulletin [Feb 2016] US$ 995.00

... on the latest events that have the potential to shape the oncology biosimilars market. Topics covered include opinions about data from Sandoz ... drive down prices to unsustainable levels and cause the biosimilars market in the US to fail? Update Bulletins include expert insight and analysis based on FirstWord ...

Feb, 2016
Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors US$ 220.00

Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors This Competitive Intelligence report titled PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors“ provides a competitor evaluation in the field of protein- and peptide-based agonists of the parathyroid hormone (PTH) receptor ...

Feb, 2016 32 pages
Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update US$ 440.00

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update The Competitive Intelligence Report Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update“ provides a competitor evaluation in the field ...

Feb, 2016 46 pages
Biosimilars in Oncology: KOL Insight US$ 7,900.00

... to accept biosimilars of proven targeted treatments. So what do pharma companies need to do to increase confidence and ensure uptake of biosimilars in this toughest of markets? Biosimilars in Oncology: KOL Insight spells out the concerns about equivalence, evidence and endpoints with insights into the current ...

Jan, 2016
Biosimilars: Regulatory Outlook US$ 2,100.00

... significant regulatory progress has been made in recent years, clarity is distinctly lacking on certain issues, such as interchangeability and naming.  FirstWord’s Biosimilars: Regulatory Outlook provides insight and opinion on why. This 64 page report gives in-depth and candid views on what eight industry and biosimilar experts ...

Nov, 2015
US Biosimilars Market Opportunity & Clinical Pipeline Analysis US$ 2,400.00

... Biosimilars Market Impact of Biosimilars in US Market Impact of Reimbursement Policies on US Biosimilars Market Zarxio: First Approved Biosimilar in US US Biosimilar Clinical Pipeline By Company, Indication & Phase US Biosimilar Clinical Pipeline: 104 Biosimilars Marketed Biosimilars: 1 Biosimilar ...

Feb, 2016 330 pages
Biosimilars Market: By Product (Recombinant Glycosated Proteins, Others) Technology (Chromatography, Mass Spectroscopy, Electrophoresis, Others) Application (Blood & Oncology Diseases,... US$ 5,250.00

... drugs also increase leading to increase in biosimilars market. The global market for the biosimilars is segmented into different product types by technology and application. Each of these ... and comprehensive analysis of biosimilars market Regulations for biosimilars play a vital role as they maintain a balance between original & biosimilar products. Currently the geographic biosimilar market is segmented into ...

Aug, 2015 86 pages
Japan Biosimilar- Active Players In Quest of a Specialty & Niche BS space US$ 4,000.00 US$ 3,600.00

... with Celltrion-NK Remicade biosimilar in 2014/2015 in the Japan pharma market demonstrated more flexibility for EU- Ex-Japan data by JP regulatory ... specialty therapy area- like ophthalmology BS (Lucentis), Enzyme therapy BS (JCR) In this report, we attempt to analyze trend/requirement of regulatory approval of ...

Jan, 2016 101 pages
Global Biosimilars Sales 2015 Market Research Report US$ 4,000.00

The Global Biosimilars Sales 2015 Market Research Report is a professional and in-depth study on the current state of the Biosimilars market. The report provides a basic overview of the Biosimilars industry ... the global Biosimilars market size (volume and value), and the sales segment market is also discussed by product type, application and region. The major Biosimilars market (including ...

Dec, 2015 162 pages
Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2016 US$ 1,450.00

... Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2016” discusses the global insulin biosimilar industry. Report analyzes that Insulin and Insulin Biosimilars ...

Feb, 2016 79 pages
Europe Biosimilars Market Opportunity Outlook 2020 US$ 2,400.00

... European biosimilars market. “Europe Biosimilars Market Opportunity Outlook 2020” Report Highlight: Europe Biosimilars Market Outlook Europe Biosimilars Market Trend Analysis by Country Introduction of Biosimilars in European Market by Segment Clinical & Non Clinical Guidelines Europe Biosimilar ...

Nov, 2015 310 pages
Global Adalimumab Biosimilar Industry Report 2015 US$ 3,100.00

The Global Adalimumab Biosimilar Industry Report 2015 is a professional and in-depth study on the current state of the Adalimumab Biosimilar industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Adalimumab Biosimilar market ...

Oct, 2015 136 pages
World Biosimilars/Follow-on-Biologics Market - Opportunities and Forecasts, 2014 - 2020 US$ 4,515.00

... data about changing market trends, competition and opportunities in biosimilars market are provided in the ... market dynamics Identification of key investment pockets in the biosimilars market would help the stakeholders in making informed decisions Key Deliverables Global biosimilars/follow-on-biologics market ...

Sep, 2015 120 pages
Analysis of USFDA's Approval of Biosimilars Case in Focus: Zarxio (Biosimilar of Amgens Neupogen) US$ 1,000.00

... Regulations around approval biosimilars in the US An overview of global biosimilar market Case study on the US approval of Zarxio (Biosimilar of Amgen’s ... Business Portfolio Planning Strategic/Business Analysis Business Development Licensing Technical Analysis Portfolio Management/Planning Project Management ...

Sep, 2015
Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis US$ 460.00

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis The Competitive Intelligence report Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis describes product ... G-CSF products represent an attractive market size for biosimilar proteins in regulated markets. Biosimilar filgrastim products have already been introduced into the the ...

Jul, 2015 76 pages
Global Biosimilars Industry 2015 Market Research Report US$ 2,850.00

2015 Global Biosimilars Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Biosimilars industry, focusing on the main regions ... with: 1.) basic information; 2.) the Asia Biosimilars industry; 3.) the North American Biosimilars industry; 4.) the European Biosimilars industry; 5.) market entry and investment feasibility; and ...

Jul, 2015 170 pages
Global & USA BioSimilar Market Analysis to 2021; BioBetters, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte Colony-Stimulating Factor (G-CSF), Anti-Tumor Necrosis Factor... US$ 3,400.00

... biosimilars into the U.S., which happens to be the largest market for biopharmaceuticals. This report provides a comprehensive overview of the size of biosimilars’ market, the segmentation of the market ...

Aug, 2015 271 pages
The Future of Biosimilars 2015 US$ 2,100.00

... the future of the biosimilars market A Report for the Entire Industry The biosimilars market is evolving quickly, making Future of Biosimilars 2015 a must-read reference not only for those working in biosimilars competitive intelligence ...

Jun, 2015 120 pages
Physician Views: Will Patient Switching Studies Support Biosimilar Adoption? US$ 695.00

... market will at some point provide a secondary benchmark for biosimilar developers, physicians, patients and payers, when data from a much anticipated 500-patient switching study ... in the EU5 the following questions this week… Has your view towards current/future usage of biosimilar TNF inhibitors become more ...

Jun, 2015
BIOSIMILARS - Regulatory Framework and Pipeline Analysis US$ 2,995.00

BIOSIMILARS - Regulatory Framework and Pipeline Analysis Summary Biosimilars are copied versions of biologics that offer a 20-50% reduction in cost compared with innovative biologic products. Biosimilars are ... dynamics: Trends, Drivers, and Barriers WHO guidance for biosimilars Regulatory overview, biosimilar guidelines, regulatory framework for biosimilars, and market outlook for: Europe, USA, India ...

Jun, 2015 94 pages
Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars US$ 750.00

... latest Chinese guidance for development, evaluation, license approval of biosimilars, Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars provided a comprehensive and thorough knowledge of the latest Chinese guidance for development, evaluation, license approval of biosimilars ...

May, 2015 48 pages
Evolution of Technologies for Therapeutic Antibodies-From mAbs to Biosimilars US$ 1,999.00

The report provides in-depth information on technologicial platforms being developed for monoclonal antibodies and how they have been improvised for biosimilar development. Also various issues pertaining to manufacturing of biosimilars have been highlighted with possible solutions to to address the hurdles.

Jan, 2015 64 pages
Physician Views: Oncologists React to Approval of Zarxio – the First US Biosimilar US$ 695.00

... for. FirstWord polled US-based oncologists on this issue, among others, following the ODAC meeting in January (see Physician Views Poll Results: Positive FDA sentiment for biosimilar Neupogen shared by oncologists). While Zarxio is a trailblazer in the ...

Mar, 2015
Physician Views: CMS Guidance on Biosimilar Reimbursement – What Do Oncologists and Rheumatologists Think? US$ 695.00

... physician sentiment to the CMS guidance. In our first poll, focused on Part B reimbursement, we are asking oncologists… How effective they expect the CMS reimbursement guidance to be in incentivising physicians ... of 'de-facto' interchangeability via CMS guidance Their view on interchangeability status for ...

Apr, 2015
Biosimilars: US Payer Perspectives US$ 2,100.00

... from some leading investment banks claiming that biosimilars in the US are on the cusp of greatness. Biosimilars: US Payer Perspectives provides a much needed tonic to perhaps the overly optimistic sentiment that has seeped into the discussions about the US biosimilars opportunity ...

Apr, 2015
Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors US$ 1,500.00

Competitor Analysis: The rapeutic Antibodies 2015: Biosimilars & Biosuperiors This Competitive Intelligence Report about The rapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor ...

Apr, 2015 414 pages
Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders US$ 6,900.00

... , Spain and Italy, Medical Affairs Reputations (EU5): Biosimilar mAbs in Inflammatory Disorders offers insights on how Medical Affairs teams from companies developing and marketing biosimilar anti-TNF monoclonal ... , Spain, the UK; EU5 – biosimilar mAb developers and companies marketing branded mAbs require solid evidence upon which to base medical affairs’ strategy for their ...

Feb, 2015
Biosimilars: European Payer Perspectives (2016) US$ 695.00

... the biosimilar industry do to help its cause? This report identifies the issues that payers identify as critical to the continued growth and adoption of biosimilars. Biosimilars: European Payer Perspectives is informed with candid insights of 15 European payers from the five leading European markets ...

Jan, 2016
Biosimilars (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 US$ 3,495.00

Biosimilars (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 SUMMARY Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the ... Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Biosimilars including ...

Dec, 2014 82 pages
2015 Deep Research Report on Global Biologics and Biosimilars Industry US$ 2,600.00

2015 Deep Research Report on Global Biologics and Biosimilars Industry is a professional and ... analysis, investment return analysis, and development trend analysis. In conclusion, it is a deep research report on Global Biologics and Biosimilars industry. Here, we express ...

Feb, 2015 170 pages
Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin US$ 390.00

Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin This Competitive Intelligence Report about Her2 Antibodies 2015 - Biosimilars and ... and make out about 81% of the franchise sale. Therefore, the Her2 antibody market is not only highly attractive for biosimilar developments ...

Feb, 2015 64 pages
Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis US$ 460.00

Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis This Competitive Intelligence Report about VEGF and VEGF-R ... more cancer and eye disease indications. The commercial success of the VEGF antibodies and the expiry of patent protection has laid the ground ...

Feb, 2015 79 pages
Global Biosimilar Market Trends & Opportunities: 2015 Edition US$ 800.00

... “Global Biosimilar Market: Trends & Opportunities (2015 Edition)” analyzes the global biologics market, with exhaustive discussion on demand of Biosimilars with increase in patent expiry of innovator drugs. The key market ... titled “The Global Biosimilar Market: Trends & Opportunities (2014-2018)” provides an in-depth analysis of the growing Biosimilar Market with detailed analysis of market sizing and growth, market share and ...

Jan, 2015 80 pages
New Phase of Mab biosimilar knocks the door Biosimilar Opportunities In Japan US$ 4,000.00 US$ 3,600.00

... Japan biosimilar market. Consolidation activities are in place for biosimilar entry by a couple of big players (Daiichi-Sankyo, KHK), JP Innovator+ GE companies (Meiji, Fujifilm, Nippon Kayaku, Mochida, and Kissei ...

Jan, 2015 65 pages
Physician Views: What opportunity for biosimilar basal insulin? US$ 695.00

... have historically had minimal opportunity to leverage discounts from an oligopolistic ... well established players, it remains to be seen how comfortable physicians would be using a 'biosimilar' insulin developed by ... as 'interchangeable' with branded Lantus). Similarly, what percentage of patients would you be ...

Nov, 2014
Physician Views: Biosimilar Lucentis – what opportunity? US$ 695.00

... Lucentis, while the availability of compounded Avastin, used as an alternative to Lucentis at a much cheaper cost, adds further confusion to the market outlook. Furthermore, a Physician Views ... therapies persists). FirstWord's Biosimilar Index reveals just one biosimilar Lucentis product in development; PF582 ...

Oct, 2014
Europe Biosimilars Market & Pipeline Insight US$ 2,400.00

... (epoetin zeta), Silapo (epoetin zeta), Tevagrastim (filgrastim), Zarzio (filgrastim), Wepox (epoetin alfa) “Europe Biosimilars Market & Pipeline Insight” Report Highlight: Biosimilars Market Overview & Trend Analysis by Country Biosimilars Introduction Timeline in Europe Biosimilars Development & ...

Oct, 2014 360 pages
Biosimilars - Biosimilars on the Cusp of a New Era US$ 2,995.00

... and launches of new biosimilar products The position of HTA and P&R agencies on biosimilars Industry perspective on the expected impact of biosimilars The biosimilars pipeline and key future developments Key companies involved in biosimilars The way ...

Jul, 2014 58 pages
Global Biosimilars Market Regulations & Pipeline Insight US$ 2,400.00

... , the monoclonal antibodies (mAbs) and insulin market would witness maximum growth, with these two segments accounting for a dominant share ... drugs losing their patents by 2020. “Global Biosimilars Market Regulations & Pipeline Insight” Report Highlights: Market Overview Detailed Regulatory Pathways For ...

Sep, 2014 836 pages
Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis,... US$ 4,515.00

... DELIVERABLES Global biosimilars/follow-on-biologics market is categorized into technology, product types, applications, services and geography. MARKET BY TECHNOLOGY Monoclonal Antibodies (MAb) Technology Recombinant DNA Technology (rDNA technology) Nuclear magnetic resonance (NMR) technology ...

Jul, 2014 184 pages
PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market US$ 2,995.00

PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market SUMMARY GlobalData’s report, 'PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market', provides strategic analysis of the global biosimilars industry. It discusses key market trends, regulatory requirements ...

Jun, 2014 173 pages
Physician Views: New FDA biosimilar guidance – an initial reaction from oncologists and rheumatologists US$ 695.00

... , the FDA published new guidance on the requirements for developing biosimilars for the US market – specifically focused on clinical pharmacology requirements ... , but potentially how they are used by physicians. In light of the FDA's new guidance, FirstWord is polling US-based oncologists and rheumatologists ...

May, 2014
The Future of Biosimilars: mapping critical uncertainties and the impact of future events US$ 1,950.00

... , to legal challenges and questions about its profitability, The Future of Biosimilars: Mapping Critical Uncertainties and the Impact of Future Events provides ... and most up-to-date access to recent and future events in the biosimilars market, including battles being waged over policy, regulatory, intellectual ...

May, 2014 125 pages
Physician Views – Are physicians getting the biosimilar education they need? US$ 695.00

... are physicians ready for biosimilars and is the industry doing enough to educate who is arguably the key stakeholder in this market? As physician ... for biosimilar developers and Physician Views: At least some similarity needed in biosimilar naming conventions, say majority of physicians, but caveats remain In a ...

Apr, 2014
Biosimilar Index: Tracking the Global Biosimilar Pipeline US$ 5,295.00

... is not, significant. That is where the Biosimilar Index comes in. A new force in biosimilar and NCB drug and market tracking FirstView’s Biosimilar Index is a new, comprehensive drug intelligence ... both on-going tracking of development and interpretation of the commercial and clinical significance. Two class beating services in one subscription! Biosimilar Index: Pipeline Database ...

Apr, 2014
Physician Views: Biosimilar naming conventions – what do physicians think? US$ 695.00

... what do physicians think? What do they consider to be the correct naming convention and how will this impact their potential usage of biosimilars. This week's Physician Views poll will ask US and EU5-based oncologists and rheumatologists: What naming convention for biosimilar products they believe ...

Feb, 2014
1 2 3 >
Skip to top